Innovation crisis in the pharmaceutical industry? A survey
Tóm tắt
In the literature, it is widely discussed whether the pharmaceutical industry is going through an innovation crisis. Unfortunately, no comprehensive review exists to date that outlines the main empirical findings. In this paper, we provide an extensive survey on what is currently known about the crisis and its reasons. The empirical evidence shows that project success rates decreased over time, while attrition rates, development times, and the costs per new drug increased. The reasons for these developments are quite complex. The crisis seems to have largely technological causes. The enormous scientific progress in biotechnology and related disciplines has increased the opportunities to treat diseases, but the firms have difficulties transforming these advances into new and effective medicines. More basic research is necessary and the links between science and industry should be strengthened. Some measures have recently been taken to better adapt the approval process to current developments. However, the persistently high number of consolidations in the industry seems to have largely detrimental effects.
Từ khóa
Tài liệu tham khảo
Abrantes-Metz R, Adams C, Metz A (2004) Pharmaceutical development phases: A duration analysis. Bureau of Economics, Federal Trade Commission, Working Paper No. 274. https://doi.org/10.2139/ssrn.607941. Accessed 15 Jan 2020
Adams C, Brantner V (2006) Estimating the cost of new drug development: Is it really $802 million? Health Aff 25(2):420–428. https://doi.org/10.1377/hlthaff.25.2.420
Adams C, Brantner V (2010) Spending on new drug development. Health Econ 19(2):130–141. https://doi.org/10.1002/hec.1454
Akhtar A (2015) The flaws and human harms of animal experimentation. Camb Q Healthc Ethics 24(4):407–419. https://doi.org/10.1017/S0963180115000079
Aronson J, Green A (2020) Me-too pharmaceutical products: History, definitions, examples, and relevance to drug shortages and essential medicines lists. Br J Clin Pharmacol 86(11):2114–2122. https://doi.org/10.1111/bcp.14327
Arora A, Gambardella A, Magazzini L, Pammolli F (2009) A breath of fresh air? Firm type, scale, scope, and selection effects in drug development. Manage Sci 55(10):1638–1653. https://doi.org/10.1287/mnsc.1090.1055
Backfisch M (2017) Have pharmaceutical R&D project success rates decreased? A critical review and new empirical results. MAGKS Discussion Paper No. 46–2017, Philipps-University Marburg, School of Business and Economics. https://www.uni-marburg.de/fb02/makro/forschung/magkspapers/paper_2017/46-2017_backfisch.pdf. Accessed 19 Feb 2020
Backfisch M (2018) The development of firm size and innovativeness in the pharmaceutical industry between 1989 and 2010. MAGKS Discussion Paper No. 13–2018. Philipps-University Marburg, School of Business and Economics. https://www.uni-marburg.de/fb02/makro/forschung/magkspapers/paper_2018/13-2018_backfisch.pdf. Accessed 19 Febr 2020
Baird L, Banken R, Eichler H et al (2014) Accelerated access to innovative medicines for patients in need. Clin Pharmacol Ther 96(5):559–571. https://doi.org/10.1038/clpt.2014.145
Begley C, Ioannidis J (2015) Reproducibility in science - improving the standard for basic and preclinical research. Circ Res 116(1):116–126. https://doi.org/10.1161/CIRCRESAHA.114.303819
Belderbos R, Gilsing V, Suzuki S (2016) Direct and mediated ties to universities: “Scientific” absorptive capacity and innovation performance of pharmaceutical firms. Strateg Organ 14(1):32–52. https://doi.org/10.1177/1476127015604734
Berndt E, Gottschalk A, Philipson T, Strobeck M (2005) Industry funding of the FDA: Effects of PDUFA on approval times and withdrawal rates. Nat Rev Drug Discov 4:545–554. https://doi.org/10.1038/nrd1774
Betz U (2011) Portfolio management in early-stage drug discovery – a traveler’s guide through uncharted territory. Drug Discov Today 16:609–618. https://doi.org/10.1016/j.drudis.2011.04.012
Bienz-Tadmor B, DiCerbo P, Tadmor G, Lasagna L (1992) Biopharmaceuticals and conventional drugs: Clinical success rates. Nat Biotechnol 10:521–525. https://doi.org/10.1038/nbt0592-521
Bolisis W, Fay M, Kühler T (2020) Use of real-world data for new drug applications and line extensions. Clin Ther 42(5):926–938. https://doi.org/10.1016/j.clinthera.2020.03.006
Bothwell L, Avorn J, Khan N, Kesselheim A (2018) Adaptive design clinical trials: a review of the literature and ClinicalTrials.gov. BMJ Open 8(2):e018320. https://doi.org/10.1136/bmjopen-2017-018320
Bowen A, Casadevall A (2015) Increasing disparities between resource inputs and outcomes, as measured by certain health deliverables, in biomedical research. Proceed Natl Acad Sci USA 112(36):11335–11340. https://doi.org/10.1073/pnas.1504955112
Branch S, Agranat I (2014) “New drug” designations for new therapeutic entities: new active substance, new chemical entity, new biological entity, new molecular entity. J Med Chem 57(21):8729–8765. https://doi.org/10.1021/jm402001w
Bunnage M (2011) Getting pharmaceutical R&D back on target. Nat Chem Biol 7:335–339. https://doi.org/10.1038/nchembio.581
Buonansegna E, Salomo S, Maier A, Li-Ying J (2014) Pharmaceutical new product development: why do clinical trials fail? R&D Manag 44(2):189–202. https://doi.org/10.1111/radm.12053
Butler D (2008) Translational research: Crossing the valley of death. Nature 453:840–842. https://doi.org/10.1038/453840a
CBO (2006) Research and Development in the Pharmaceutical Industry. Congress of the United States, Congressional Budget Office. https://www.cbo.gov/sites/default/files/cbofiles/ftpdocs/76xx/doc7615/10-02-drugr-d.pdf. Accessed 23 Aug 2018
Chu W (2006) Has new technology hampered R&D productivity? William Reed Business Media Ltd. Crawley, England. https://www.outsourcing-pharma.com/Article/2006/03/30/Has-new-technology-hampered-R-D-productivity?utm_source=copyright&utm_medium=OnSite&utm_campaign=copyright. Accessed 12 Aug 2018
Cockburn I (2006) Is the pharmaceutical industry in a productivity crisis? Innov Policy Econ 7:1–32. https://doi.org/10.1086/ipe.7.25056188
Cockburn I, Henderson R (2001) Scale and scope in drug development: unpacking the advantages of size in pharmaceutical research. J Health Econ 20(6):1033–1057. https://doi.org/10.1016/S0167-6296(01)00108-4
Cohen W, Levinthal D (1990) Absorptive capacity: a new perspective on learning and innovation. Adm Sci Q 35(1):128–152. https://doi.org/10.2307/2393553
Comanor W, Scherer F (2013) Mergers and innovation in the pharmaceutical industry. J Health Econ 32(1):106–113. https://doi.org/10.1016/j.jhealeco.2012.09.006
Coombs R, Metcalfe S (2002) Innovation in pharmaceuticals: perspectives on the co-ordination, combination and creation of capabilities. Technol Anal Strateg Managt 14(3):261–271. https://doi.org/10.1080/095373202200002104
Corrigan-Curay J, Sacks L, Woodcock J (2018) Real-world evidence and real-world data for evaluating drug safety and effectiveness. JAMA 320(9):867–868. https://doi.org/10.1001/jama.2018.10136
Cowlrick I, Hedner T, Wolf R, Olausson M, Klofsten M (2011) Decision-making in the pharmaceutical industry: analysis of entrepreneurial risk and attitude using uncertain information. R&D Management 41(4):321–336. https://doi.org/10.1111/j.1467-9310.2011.00649.x
Cunningham C, Ederer F, Ma S (2021) Killer Acquisitions. J Polit Econ 129(3):649–702. https://doi.org/10.1086/712506
Danzon P, Nicholson S, Pereira N (2005) Productivity in pharmaceutical-biotechnology R&D: the role of experience and alliances. J Health Econ 24(2):317–339. https://doi.org/10.1016/j.jhealeco.2004.09.006
Danzon P, Epstein A, Nicholson S (2007) Mergers and acquisitions in the pharmaceutical and biotech industries. Manag Decis Econ 28:307–328. https://doi.org/10.1002/mde.1343
Danzon P, Keuffel E (2014) Regulation of the Pharmaceutical-Biotechnology Industry. In: Rose N (ed) Economic Regulation and Its Reform: What Have We Learned? University of Chicago Press, Chicago, pp 407–484
Darrow J, Avorn J, Kesselheim A (2014) New FDA breakthrough-drug category – implications for patients. N Engl J Med 370:1252–1258. https://doi.org/10.1056/NEJMhle1311493
Da Silva M (2019) Open innovation and IPRs: Mutually incompatible or complementary institutions? J Innov Knowl 4(4):248–252. https://doi.org/10.1016/j.jik.2018.03.010
Deeds D, Hill C (1996) Strategic alliances and the rate of new product development: An empirical study of entrepreneurial biotechnology firms. J Bus Ventur 11(1):41–55. https://doi.org/10.1016/0883-9026(95)00087-9
De Man AP, Duysters G (2005) Collaboration and innovation: A review of the effects of mergers, acquisitions and alliances on innovation. Technovation 25(12):1377–1387. https://doi.org/10.1016/j.technovation.2004.07.021
DiMasi J (2001) Risks in new drug development: Approval success rates for investigational drugs. Clin Pharmacol Ther 69(5):297–307. https://doi.org/10.1067/mcp.2001.115446
DiMasi J, Hansen R, Grabowski H, Lasagna L (1991) Cost of innovation in the pharmaceutical industry. J Health Econ 10(2):107–142. https://doi.org/10.1016/0167-6296(91)90001-4
DiMasi J, Grabowski H, Vernon J (1995) R&D costs, innovative output and firm size in the pharmaceutical industry. Int J Econ Bus 2(2):201–219. https://doi.org/10.1080/758519309
DiMasi J, Hansen R, Grabowski H (2003) The price of innovation: new estimates of drug development costs. J Health Econ 22(2):151–185. https://doi.org/10.1016/S0167-6296(02)00126-1
DiMasi J, Grabowski H, Hansen R (2016) Innovation in the pharmaceutical industry: New estimates of R&D costs. J Health Econ 47:20–33. https://doi.org/10.1016/j.jhealeco.2016.01.012
Disis M, Slattery J (2010) The road we must take: Multidisciplinary team science. Sci Transl Med. 2(22):22cm9. https://doi.org/10.1126/scitranslmed.3000421
Dong J, McCarthy K (2019) When more isn’t merrier: Pharmaceutical alliance networks and breakthrough innovation. Drug Discovery Today 24(3):673–677. https://doi.org/10.1016/j.drudis.2019.01.002
Dong J, McCarthy K, Schoenmakers W (2017) How central is too central? Organizing interorganizational collaboration networks for breakthrough innovation. J Prod Innov Manag 34(4):526–542. https://doi.org/10.1111/jpim.12384
Drews J (2000) Quo vadis, biotech? (Part 1). Drug Discov Today 5(12):547–553. https://doi.org/10.1016/S1359-6446(00)01580-4
EFPIA (2010) The Pharmaceutical Industry in Figures – 2010 Edition. Report of the European Federation of Pharmaceutical Industries and Associations. https://www.sfee.gr/wp-content/uploads/2015/05/Figures_2010_Final-20100611-001-EN-v1_0.pdf. Accessed 10 March 2020
EFPIA (2014) The Pharmaceutical Industry in Figures – Key Data 2014. Report of the European Federation of Pharmaceutical Industries and Associations. https://www.phar-in.eu/wp-content/uploads/2014/05/Figures_2014_Final.pdf. Accessed 9 March 2020
EFPIA (2015) The Pharmaceutical Industry in Figures – Key Data 2015. Report of the European Federation of Pharmaceutical Industries and Associations. https://www.efpia.eu/media/25822/2015-the-pharmaceutical-industry-in-figures.pdf. Accessed 10 March 2020
EFPIA (2017) The Pharmaceutical Industry in Figures – Key Data 2017. Report of the European Federation of Pharmaceutical Industries and Associations. https://www.efpia.eu/media/219735/efpia-pharmafigures2017_statisticbroch_v04-final.pdf. Accessed 21 Jan 2020
EFPIA (2018) The Pharmaceutical Industry in Figures – Key Data 2018. Report of the European Federation of Pharmaceutical Industries and Associations. https://efpia.eu/media/361960/efpia-pharmafigures2018_v07-hq.pdf. Accessed 10 March 2020
EFPIA (2019) The Pharmaceutical Industry in Figures – Key Data 2019. Report of the European Federation of Pharmaceutical Industries and Associations. https://www.efpia.eu/media/413006/the-pharmaceutical-industry-in-figures.pdf. Accessed 10 March 2020
Eichler H, Baird L, Barker R et al (2015) From adaptive licensing to adaptive pathways: delivering a flexible life-span approach to bring new drugs to patients. Clin Pharmacol Ther 97(3):234–246. https://doi.org/10.1002/cpt.59
EMA (2016a) Final report on the adaptive pathways pilot. European Medicines Agency. https://www.ema.europa.eu/en/documents/report/final-report-adaptive-pathways-pilot_en.pdf. Accessed 10 March 2020
EMA (2016b) Guidance for companies considering the adaptive pathways approach. European Medicines Agency. https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guidance-companies-considering-adaptive-pathways-approach_en.pdf. Accessed 10 March 2020
EMA (2020) Guideline on registry-based studies – Draft. European Medicines Agency. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-registry-based-studies_en.pdf. Accessed 20 Febr 2021
Ernst H, Vitt J (2000) The influence of corporate acquisitions on the behavior of key inventors. R&D Manag 30(2):105–119. https://doi.org/10.1111/1467-9310.00162
Evaluate (2017) Evaluate Pharma, World Preview 2017, Outlook to 2022. Evaluate Ltd. http://www.evaluate.com/PharmaWorldPreview2017. Accessed 12 Aug 2018
Evaluate (2019) Evaluate Vantage 2020 Preview. Evaluate Ltd. https://www.evaluate.com/thought-leadership/vantage/evaluate-vantage-2020-preview#download. Accessed 27 Aug 2020
Evens R (2016) Pharma success in product development – does biotechnology change the paradigm in product development and attrition. AAPS J 18(1):281–285. https://doi.org/10.1208/s12248-015-9833-6
Fagerberg J (2005) Innovation: A guide to the literature. In: Fagerberg J, Mowery D (eds) The Oxford Handbook of Innovation. University Press, Oxford, pp 1–26
FDA (2018a) New Drugs at FDA: CDER’s New Molecular Entities and New Therapeutic Biological Products. US Food and Drug Administration. https://www.fda.gov/drugs/development-approval-process-drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products. Accessed 10 March 2020
FDA (2018b) Summary of NDA Approvals & Receipts, 1938 to the Present. US Food and Drug Administration. https://www.fda.gov/about-fda/histories-product-regulation/summary-nda-approvals-receipts-1938-present. Accessed 9 March 2020
FDA (2018c) Framework for FDA’s Real-World Evidence Program. US Food and Drug Administration. https://www.fda.gov/media/120060/download. Accessed 20 Febr 2021
FDA (2019a) Advancing Health through Innovation, New Drug Therapy Approvals 2019. Center for Drug Evaluation and Research. US Food and Drug Administration. https://www.fda.gov/media/134493/download. Accessed 9 March 2020
FDA (2019b) Adaptive Designs for Clinical Trials of Drugs and Biologics, Guidance for Industry. US Food and Drug Administration. https://www.fda.gov/media/78495/download. Accessed 20 Febr 2021
Frank R (2003) New estimates of drug development costs. J Health Econ 22(2):325–330. https://doi.org/10.1016/S0167-6296(03)00002-X
Gagne J, Choudhry N (2011) How many “me-too” drugs is too many? J Am Med Assoc 305(7):711–712. https://doi.org/10.1001/jama.2011.152
Garnier JP (2008) Rebuilding the R&D engine in big pharma. Harv Bus Rev 86(5):68–76
Gassmann O, Reepmeyer G (2005) Organizing pharmaceutical innovation: From science-based knowledge creators to drug-oriented knowledge brokers. Creat Innov Manag 14(3):233–245. https://doi.org/10.1111/j.1467-8691.2005.00344.x
Gassmann O, Reepmeyer G, von Zedtwitz M (2008) Leading Pharmaceutical Innovation: Trends and Drivers for Growth in the Pharmaceutical Industry, 2nd edn. Springer, Berlin
Gilman B, Kautter J (2008) Impact of multitiered copayments on the use and cost of prescription drugs among medicare beneficiaries. Health Serv Res 43(2):478–495. https://doi.org/10.1111/j.1475-6773.2007.00774.x
Grabowski H, Kyle M (2012) Mergers, acquisitions, and alliances. In: Danzon P, Nicholson S (eds) The Oxford Handbook of the Economics of the Biopharmaceutical Industry. University Press, Oxford, pp 552–579
Granstrand O, Sjölander S (1990) The acquisition of technology and small firms by large firms. J Econ Behav Organ 13(3):367–386. https://doi.org/10.1016/0167-2681(90)90006-Y
Hall B (1999) Mergers and R&D revisited. Paper prepared for the Quasi-Experimental Methods Symposium. Econometrics Laboratory, UC Berkeley. https://www.researchgate.net/profile/Bronwyn-Hall-3/publication/2353839_Mergers_and_RD_Revisited/links/0c96051f981c9ec90e000000/Mergers-and-R-D-Revisited.pdf. Accessed 10 March 2020
Hay M, Thomas D, Craighead J, Economides C, Rosenthal J (2014) Clinical development success rates for investigational drugs. Nat Biotechnol 32:40–51. https://doi.org/10.1038/nbt.2786
Henderson R (2000) One point of view: Drug industry mergers won’t necessarily benefit R&D. Res Technol Manag 43(4):10–11
Hitt M, Hoskisson R, Ireland D, Harrison J (1991) Effects of acquisitions on R&D inputs and outputs. Acad Manag J 34(3):693–711. https://doi.org/10.5465/256412
Hopkins M, Martin P, Nightingale P, Kraft A, Mahdi S (2007) The myth of the biotech revolution: An assessment of technological, clinical and organizational change. Res Policy 36(4):566–589. https://doi.org/10.1016/j.respol.2007.02.013
IFPMA (2017) The Pharmaceutical Industry and Global Health. Facts and Figures 2017. International Federation of Pharmaceutical Manufacturers & Associations. https://www.ifpma.org/wp-content/uploads/2017/02/IFPMA-Facts-And-Figures-2017.pdf. Accessed 19 Jan 2020
IMS Institute (2015) Global Medicines Use in 2020 – Outlook and Implications. IMS Institute for Healthcare Informatics. https://www.iqvia.com/-/media/iqvia/pdfs/institute-reports/global-medicines-use-in-2020. Accessed 15 Jan 2020
Informa (2019) Pharma R&D Annual Review 2019. Pharmaprojects, Pharma Intelligence, Informa Ltd. https://pharmaintelligence.informa.com/~/media/informa-shop-window/pharma/2019/files/whitepapers/pharma-rd-review-2019-whitepaper.pdf. Accessed 19 Jan 2020
Ioannidis J (2005) Why most published research findings are false. PLoS Med 2(8):e124. https://doi.org/10.1371/journal.pmed.0020124
Ioannidis J (2016) Why most clinical research is not useful. PLoS Med 13(6):e1002049. https://doi.org/10.1371/journal.pmed.1002049
Jommi C, Armeni P, Costa F, Bertolani A, Otto M (2020) Implementation of Value-based Pricing for Medicines. Clin Ther 42(1):15–24. https://doi.org/10.1016/j.clinthera.2019.11.006
Kaitin K, DiMasi J (2011) Pharmaceutical innovation in the 21st century: new drug approvals in the first decade, 2000–2009. Clin Pharmacol Ther 89(2):183–188. https://doi.org/10.1038/clpt.2010.286
Kinch M (2014) The rise (and decline?) of biotechnology. Drug Discover Today 19(11):1686–1690. https://doi.org/10.1016/j.drudis.2014.04.006
Kinch M, Haynesworth A, Kinch S, Hoyer D (2014) An overview of FDA-approved new molecular entities: 1827–2013. Drug Discov Today 19(8):1033–1039. https://doi.org/10.1016/j.drudis.2014.03.018
Kinch M, Moore R (2016) Innovator organizations in new drug development: assessing the sustainability of the biopharmaceutical industry. Cell Chem Biol 23(6):644–653. https://doi.org/10.1016/j.chembiol.2016.05.013
Kinch M, Kraft Z, Schwartz T (2021) Sources of innovation for new medicines: questions of sustainability. Drug Discov Today 26(1):240–247. https://doi.org/10.1016/j.drudis.2020.10.026
Kola I, Landis J (2004) Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 3:711–716. https://doi.org/10.1038/nrd1470
Laermann-Nguyen U (2015) Pharmaceutical mergers and their effect on parallel R&D paths. Paper presented at the DRUID Academy Conference in Rebild/Aalborg, Denmark. January 21–23, 2015. https://conference.druid.dk/acc_papers/rtrg5rn16q8kq7rcma21v87em7hk.pdf. Accessed 19 Jan 2020
Lakdawalla D (2018) Economics of the pharmaceutical industry. J Econ Lit 56(2):397–449. https://doi.org/10.1257/jel.20161327
LaMattina J (2011) The impact of mergers on pharmaceutical R&D. Nat Rev Drug Discov 10:559–560. https://doi.org/10.1038/nrd3514
Light D, Lexchin J (2012) Pharmaceutical research and development: what do we get for all that money? BMJ 345:e4348. https://doi.org/10.1136/bmj.e4348
Light D, Warburton R (2011) Demythologizing the high cost of pharmaceutical research. BioSocieties 6:34–50. https://doi.org/10.1057/biosoc.2010.40
Malerba F, Orsenigo L (2015) The evolution of the pharmaceutical industry. Bus Hist 57(5):664–687. https://doi.org/10.1080/00076791.2014.975119
Mankoff S, Brander C, Ferrone S, Marincola F (2004) Lost in translation: obstacles to translational medicine. J Transl Med 2(14):1–5. https://doi.org/10.1186/1479-5876-2-14
Mansfield E (1986) Patents and innovation: an empirical study. Manag Sci 32(2):139–256. https://doi.org/10.1287/mnsc.32.2.173
Manski C (2009) Adaptive partial drug approval: a health policy proposal. Econom’ Voice. https://doi.org/10.2202/1553-3832.1449
Martin P, Hopkins M, Nightingale P, Kraft A (2009) On a Critical Path – Genomics, the Crisis of Pharmaceutical Productivity, and the Search for Sustainability. In: Atkinson P, Glasner P, Lock M (eds) The Handbook of Genetics & Society: Mapping the New Genomic Era. Routledge, New York, pp 145–162
Miller D (2012) Value-based pricing: examples of healthcare system reforms from the UK and US and implications for industry. Pharm Med 26:217–222. https://doi.org/10.1007/BF03262478
Mittra J (2007) Life science innovation and the restructuring of the pharmaceutical industry: merger, acquisition and strategic alliance behaviour of large firms. Technol Anal Strateg Manag 19(3):279–301. https://doi.org/10.1080/09537320701281540
Moher D, Liberati A, Tetzlaff J, Altmann D (2009) Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med 6(7):e1000097. https://doi.org/10.1371/journal.pmed.1000097
Mohr P, Tunis S (2010) Access with evidence development: The US experience. Pharmacoeconomics 28(2):153–162. https://doi.org/10.2165/11531050-000000000-00000
Morgan P, Van Der Graaf P, Arrowsmith J et al (2012) Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival. Drug Discov Today 17(9/10):419–424. https://doi.org/10.1016/j.drudis.2011.12.020
Munos B (2009) Lessons from 60 years of pharmaceutical innovation. Nat Rev Drug Discov 8:959–968. https://doi.org/10.1038/nrd2961
Munos B (2010) Can open-source drug R&D repower pharmaceutical innovation? Clin Pharmacol Ther 87(5):534–536. https://doi.org/10.1038/clpt.2010.26
Munos B (2016) Biomedical innovation: lessons from the past and perspectives for the future. Clin Pharmacol Ther 100(6):588–590. https://doi.org/10.1002/cpt.456
Munos B, Chin W (2011) How to revive breakthrough innovation in the pharmaceutical industry. Sci Transl Med 3(89):89cm16. https://doi.org/10.1126/scitranslmed.3002273
Ornaghi C (2009) Mergers and innovation in big pharma. Int J Ind Organ 27(1):70–79. https://doi.org/10.1016/j.ijindorg.2008.04.003
OTA (1993) Pharmaceutical R&D: Costs, Risks, and Rewards. US Congress, Office of Technology Assessment, OTA-H-522. US Government Printing Office, Washington, D.C. https://govinfo.library.unt.edu/ota/Ota_1/DATA/1993/9336.PDF. Accessed 15 Jan 2020
Pammolli F, Magazzini L, Riccaboni M (2011) The productivity crisis in pharmaceutical R&D. Nat Rev Drug Discov 10(6):428–438. https://doi.org/10.1038/nrd3405
Pammolli F, Righetto L, Abrignani S, Pani L, Pelicci P, Rabosio E (2020) The endless frontier? The recent increase in R&D productivity in pharmaceuticals. J Transl Med 18(162):1–14. https://doi.org/10.1186/s12967-020-02313-z
Paul S, Mytelka D, Dunwiddie C et al (2010) How to improve R&D productivity: the pharmaceutical industry’s grand challenge. Nat Rev Drug Discov 9:203–214. https://doi.org/10.1038/nrd3078
PhRMA (2016) Biopharmaceutical Research Industry Profile 2016. Pharmaceutical Research and Manufacturers of America. Washington, D.C. http://phrma-docs.phrma.org/sites/default/files/pdf/biopharmaceutical-industry-profile.pdf. Accessed 11 Jan 2020
Pisano G (2006) Science Business: The Promise, the Reality and the Future of Biotech. Harvard Business School University Press, Boston, MA
Posey Norris S, Pankevich D, Davis M, Altevogt B (2014) Improving and Accelerating Therapeutic Development for Nervous System Disorders. Forum on Neuroscience and Nervous System Disorders. Workshop Summary. Institute of Medicine of the National Academies of Sciences Engineering Medicine, Washington, D.C. https://doi.org/10.17226/18494
Prescrire International (2003) A review of new drugs and indications in 2002: Financial speculation or better patient care? Prescrire Int 12(64):74–77. https://english.prescrire.org/en/SummaryDetail.aspx?IssueId=64. Accessed 05 Febr 2020
Richard J, Wurtman M (1997) What went right: Why is HIV a treatable infection? Nat Med 3:714–717. https://doi.org/10.1038/nm0797-714
Roberts S, Fischhoff M, Sakowski S, Feldman E (2012) Perspective: Transforming science into medicine: How clinician-scientists can build bridges across research’s “valley of death.” Acad Med 87(3):266–270. https://doi.org/10.1097/ACM.0b013e3182446fa3
Ruffolo R (2006) Why has R&D productivity declined in the pharmaceutical industry? Expert Opin Drug Discov 1(2):99–102. https://doi.org/10.1517/17460441.1.2.99
Sams-Dodd F (2013) Is poor research the cause of the declining productivity of the pharmaceutical industry? An industry in need of a paradigm shift. Drug Discov Today 18(5/6):211–217. https://doi.org/10.1016/j.drudis.2012.10.010
Scannell J, Blanckley A, Boldon H, Warrington B (2012) Diagnosing the decline in pharmaceutical R&D efficiency. Nat Rev Drug Discovery 11:191–200. https://doi.org/10.1038/nrd3681
Scannell J, Bosley J (2016) When quality beats quantity: decision theory, drug discovery, and the reproducibility crisis. PLoS One 11(2):e0147215. https://doi.org/10.1371/journal.pone.0147215
Scherer F (2000) The pharmaceutical industry. In: Culyer AJ, Newhouse JP (eds) Handbook of Health Economics I. Elsevier, Amsterdam, pp 1298–1336
Scherer F (2010) Pharmaceutical innovation. In: Hall BH, Rosenberg N (eds) Handbook of the Economics of Innovation I. North-Holland, Amsterdam, pp 539–547
Schmid E, Smith D (2004) Is pharmaceutical R&D just a game of chance or can strategy make a difference? Drug Discov Today 9(1):18–26. https://doi.org/10.1016/S1359-6446(04)02951-4
Scott Morton F, Kyle M (2012) Markets for Pharmaceutical Products. In: Pauly M, McGuire T, Pita Barros P (eds) Handbook of Health Economics II. North-Holland, Amsterdam, pp 763–823
Seyhan A (2019) Lost in translation: the valley of death across preclinical and clinical divide – identification of problems and overcoming obstacles. Transl Med Commun. https://doi.org/10.1186/s41231-019-0050-7
Shaw D (2017) Is open science the future of drug development? Yale J Biol Med 90(1):147–151
Sherman R, Anderson S, Pan G et al (2016) Real-world evidence — what is it and what can it tell us? N Engl J Med 375(23):2293–2297. https://doi.org/10.1056/NEJMsb1609216
Thomas L (1996) Industrial Policy and International Competitiveness in the Pharmaceutical Industry. In: Helms R (ed) Competitive Strategies in the Pharmaceutical Industry. The American Enterprise Institute, Washington, D.C., pp 107–129
Thomas D, Burns J, Audette J, Carroll A, Dow-Hygelund C, Hay M (2016) Clinical Development Success Rates 2006–2015. Biotechnology Innovation Organization. https://www.bio.org/sites/default/files/legacy/bioorg/docs/Clinical%20Development%20Success%20Rates%202006-2015%20-%20BIO,%20Biomedtracker,%20Amplion%202016.pdf. Accessed 23 Febr 2021
Topol E (2004) Failing the public health – rofecoxib, merck, and the FDA. N Engl J Med 352:1707–1709. https://doi.org/10.1056/NEJMp048286
Waldman S, Terzic A (2016) Bioinnovation Enterprise: An engine driving breakthrough therapies. Clin Pharmacol Ther 99(1):8–13. https://doi.org/10.1002/cpt.272
Wong C, Siah K, Lo A (2019) Estimation of clinical trial success rates and related parameters. Biostatistics 20(2):273–286. https://doi.org/10.1093/biostatistics/kxx069
Woodcock J (2012) Evidence vs. access: can twenty-first-century drug regulation refine the tradeoffs? Clin Pharmacol Therap 91(3):378–380. https://doi.org/10.1038/clpt.2011.337